Zhitong Finance App News, Kangenbei (600572.SH) issued an announcement. Recently, Inner Mongolia Kangenbei Pharmaceutical Co., Ltd. (“Inner Mongolia Kangenbei”), a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration regarding the new indications of Musk Tongxin Drop Pills. The new indication for this application is heart failure with preserved ejection scores (dialectical gas ischemia and blood stasis in traditional Chinese medicine), and the route of administration is oral administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.